Several other research analysts also recently issued reports on the stock. Zacks Investment Research upgraded shares of Mylan N.V. from a sell rating to a hold rating in a research report on Tuesday, August 1st. Royal Bank Of Canada set a $41.00 price objective on Mylan N.V. and gave the stock a hold rating in a report on Sunday, July 16th. Citigroup Inc. raised Mylan N.V. from a neutral rating to a buy rating and boosted their price objective for the stock from $36.00 to $42.00 in a report on Wednesday, August 16th. Cowen and Company reissued a hold rating and set a $43.00 price objective on shares of Mylan N.V. in a report on Thursday, August 3rd. Finally, BidaskClub raised Mylan N.V. from a strong sell rating to a sell rating in a report on Friday, June 16th. One analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $41.21.
Mylan N.V. (MYL) traded up 1.05% during trading on Wednesday, reaching $38.58. 2,879,480 shares of the company’s stock traded hands. The company has a market capitalization of $20.69 billion, a price-to-earnings ratio of 31.19 and a beta of 1.30. Mylan N.V. has a 12 month low of $29.39 and a 12 month high of $45.87. The firm’s 50 day moving average is $33.26 and its 200-day moving average is $36.26.
Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.18 by ($0.08). The company had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The firm’s quarterly revenue was up 15.7% on a year-over-year basis. During the same quarter last year, the company earned $1.16 EPS. Analysts expect that Mylan N.V. will post $4.58 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Wells Fargo & Company Analysts Give Mylan N.V. (NASDAQ:MYL) a $32.00 Price Target” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://baseballnewssource.com/markets/wells-fargo-company-analysts-give-mylan-n-v-myl-a-32-00-price-target/1699890.html.
A number of large investors have recently added to or reduced their stakes in MYL. Ardsley Advisory Partners acquired a new stake in shares of Mylan N.V. in the 2nd quarter valued at approximately $291,000. Achmea Investment Management B.V. boosted its holdings in shares of Mylan N.V. by 76.7% in the 2nd quarter. Achmea Investment Management B.V. now owns 41,018 shares of the company’s stock valued at $1,592,000 after buying an additional 17,804 shares during the last quarter. Sentry Investment Management LLC boosted its holdings in shares of Mylan N.V. by 1.1% in the 2nd quarter. Sentry Investment Management LLC now owns 34,290 shares of the company’s stock valued at $1,331,000 after buying an additional 360 shares during the last quarter. Toronto Dominion Bank boosted its holdings in shares of Mylan N.V. by 25.7% in the 2nd quarter. Toronto Dominion Bank now owns 156,074 shares of the company’s stock valued at $6,058,000 after buying an additional 31,862 shares during the last quarter. Finally, EP Wealth Advisors LLC boosted its holdings in shares of Mylan N.V. by 7.8% in the 2nd quarter. EP Wealth Advisors LLC now owns 164,340 shares of the company’s stock valued at $6,380,000 after buying an additional 11,854 shares during the last quarter. 71.95% of the stock is owned by hedge funds and other institutional investors.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with our FREE daily email newsletter.